Key references: Induction therapy for extensive ulcerative colitis in adults

  • Adamina M, Bonovas S, Raine T, Spinelli A, Warusavitarne J, Armuzzi A, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. J Crohns Colitis 2020;14(2):155-68. https://www.ncbi.nlm.nih.gov/pubmed/31742338
  • Lichtenstein GR, Travis S, Danese S, D'Haens G, Moro L, Jones R, et al. Budesonide MMX for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis. J Crohns Colitis 2015;9(9):738-46. https://www.ncbi.nlm.nih.gov/pubmed/26094251
  • Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005;54(7):960-5. https://www.ncbi.nlm.nih.gov/pubmed/15951542
  • Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, et al. Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012;143(5):1218-26 e1-2. https://www.ncbi.nlm.nih.gov/pubmed/22892337
  • Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014;63(3):433-41. https://www.ncbi.nlm.nih.gov/pubmed/23436336